In this PACULit episode, Britany and Seth discuss a retrospective real-world study evaluating a single fixed 4.5 mg dose of rasburicase for TLS-related hyperuricemia. They explain stratification by baseline uric acid (moderate 12 to <15 mg/dL versus high ≥15 mg/dL) and report rapid uric acid reductions in both groups, with no significant differences in clinical outcomes. The discussion highlights potential cost savings, easier pharmacy workflows, and expanded access in resource-limited settings, along with safety considerations (G6PD screening, uric acid assay interference) and key limitations of retrospective data. They also outline practical takeaways and directions for future prospective trials and broader populations (pediatric and renal impairment).